预印本 / 版本 1

Single-Cell Multi-omics Decodes the Aggrephagy Landscape, Unveiling TUBA4A as a Novel Oncogene and Immunotherapeutic Target in ccRCC

本文是预印本，尚未经过同行评审认证。

作者

    Kun Cui，  Qiuxin Duan，  Zhe Xu，  Wenjing Liu，  Yueli Ni，  Yongping Li，  Lu Yuan，  Zhuoran Teng，  Yurong Dong，  Ziyuan Bai，  Asif Shahzad，  Jianshan Zhang，  Yu Dou，  Jiaojiao Xia，  Hanyue Shao，  Zhe Yang，  Qiao Zhang
    Qiao Zhang
分类
生物化学与生物物理学 分子生物学
关键词
ccRCC; aggrephagy; tumor microenvironment; prognosis

摘要

Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy with a complex and immunosuppressive tumor microenvironment (TME). While aggrephagy, a selective autophagy process, has been linked to cancer, its role in ccRCC remains unclear. Through integrated multi-omics analysis of single-cell and bulk sequencing data, we constructed the first aggrephagy activity atlas in ccRCC TME, revealing subtype-specific programs linked to immune suppression and metabolic reprogramming. High aggrephagy activity correlated with poor prognosis and immunotherapy resistance, particularly in macrophages and T cells. Among key prognostic genes, we identified TUBA4A as a novel player in ccRCC. Functional validation showed that TUBA4A enhances autophagy and promotes tumor proliferation, migration, and invasion. This study establishes aggrephagy and TUBA4A as key regulators of ccRCC progression and potential therapeutic targets. 

指标

收藏: 2
查看次数: 576
下载次数: 158

DOI：

https://doi.org/10.65215/1wp90106

Submission ID：

3

下载次数

已发布

2025-11-18

如何引用

Cui, K., Duan, Q., Xu, Z., Liu, W., Ni, Y., Li, Y., Yuan, L., Teng, Z., Dong, Y., Bai, Z., Shahzad, A., Zhang, J., Dou, Y., Xia, J., Shao, H., Yang, Z., & Zhang, Q. (2025). Single-Cell Multi-omics Decodes the Aggrephagy Landscape, Unveiling TUBA4A as a Novel Oncogene and Immunotherapeutic Target in ccRCC. 浪淘沙预印本平台. https://doi.org/10.65215/1wp90106

利益冲突声明

作者声明无任何需要披露的利益冲突。

Copyright

本预印本的版权持有者为作者/资助方。

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.